Introduction {#s1}
============

Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have shown clinical activity and marked efficacy in metastatic cancer therapy ([@B1]--[@B6]). Over recent years, many PD-1/PD-L1 inhibitors have been approved by Food and Drug Administration (FDA). For example, nivolumab and pembrolizumab (both PD-1 inhibitors) were approved for non-small cell lung cancer (NSCLC) and metastatic melanoma treatment ([@B7]--[@B10]). Atezolizumab and durvalumab were approved for NSCLC and urothelial carcinoma treatment ([@B11]--[@B14]). These regulatory approvals have resulted in a widespread prescribing of PD-1/PD-L1 inhibitors in real-world clinical practice. However, PD-1/PD-L1 inhibitors could disrupt normal immune tolerance mechanisms, thus lead to immune-related adverse events (irAEs) and other treatment-related adverse events (trAEs) ([@B15]--[@B18]).

The improvements in marked clinical efficacy should be balanced against the potentially serious or life-threatening adverse events when choosing among different therapeutic regimens. It is important for clinicians to be fully aware of the treatment-related risks and to better manage cancer treatment. To date, numerous randomized controlled trials (RCTs) have been conducted to investigate the efficacy and safety profiles of PD-1/PD-L1 inhibitors ([@B2], [@B5], [@B6], [@B19]--[@B23]). However, RCTs that are not prospectively designed with the particular safety outcome as a primary endpoint may not have sufficient sample size to detect important trAEs and irAEs. Thus, they would lack more convincing statistical power or could not reliably evaluate the potentially increased risks caused by PD-1/PD-L1 inhibitors. Moreover, head-to-head RCT, that compares PD-1/PD-L1 inhibitors against one another, is not available ([@B24]). Comparative trAEs and irAEs among different PD1/PD-L1 inhibitor-related therapeutic regimens have never been systematically studied.

Structured evidence on treatment-related safety of PD1/PD-L1 inhibitors would be necessary for clinicians in making clinical decisions. In this study, we carried out a systematic review and network meta-analysis (NMA) to compare the safety on trAEs and irAEs among different types of PD1/PD-L1 inhibitor-related therapeutic regimens simultaneously for cancer patients.

Methods {#s2}
=======

Study Design
------------

This network meta-analysis was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines ([@B25], [@B26]). A priori established review protocol was followed when this study was conducted. The review protocol was not registered.

Search Strategy and Selection Criteria
--------------------------------------

PubMed and Embase databases were systematically searched up to April 17th 2019 using the combinations of the following terms: (neoplasia OR malignancy OR melanoma) AND (nivolumab OR pembrolizumab OR lambrolizumab OR avelumab OR atezolizumab OR durvalumab OR "programmed cell death 1 receptor" OR "programmed cell death 1 ligand 1") AND (random OR control OR placebo). The detailed search strategies are listed in [Supplementary Table 1](#SM4){ref-type="supplementary-material"}. There was no restriction on language or year of publication. We manually checked reference lists of related review articles and published trials to identify additional studies.

Studies were selected when they met the following inclusion criteria: (1) either PD-1 inhibitors (i.e., nivolumab, pembrolizumab) or PD-L1 inhibitors (i.e., atezolizumab, avelumab, durvalumab), alone or in combination with chemotherapy/placebo, were included in at least one of the treatment arms; (2) either PD-1/PD-L1 inhibitors, chemotherapy or placebo were included in the control arms; (3) treatment-related and/or immune-related adverse events were reported; (4) phase II or III RCTs. We excluded: (1) studies only in conference abstracts or posters form or presentations of ongoing trials; (2) study protocols, review, or commentary; (3) *in vitro* or animal studies; (4) studies which only involved quality-of-life outcomes or cost effectiveness analyses. Two investigators (HY, FH) selected the potentially eligible studies independently. The titles, abstracts, and full texts were evaluated sequentially.

Data Extraction
---------------

Two independent investigators (HY and FH) extracted the data from all the eligible studies. The following information was extracted: trial name, line of treatment, study phase, blinding, median age (range), sex, tumor type, types, and dosage of drugs, number of patients in each randomization arm, median length of follow-up, number of patients in the safety dataset, number of patients with high-grade (grade 3--5) and all-grade (grade 1--5) treatment-related adverse events (trAEs), number of patients with high-grade and all-grade immune-related adverse events (irAEs). When more than one article reported the same outcome, we used the most updated data.

Quality Assessment
------------------

The risk of bias was assessed independently by two authors (HY and FH) using Review Manager 5.3 software. The following domains were assessed: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants, and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other bias ([@B27]).

The Grading of Recommendations Assessment, Development, and Evaluation system (GRADE) approach was used to rate the quality of evidence ([@B28]). The four levels of evidence quality including high, moderate, low, and very low. The quality of evidence for each outcome was based on the fundamental study design and additional methodological factors.

Outcome Measures
----------------

The term immune-related adverse events (irAEs) would not be appropriate to describe the chemotherapy toxicity. Therefore, treatment-related adverse events (trAEs) of both all-grade and high-grade were selected as the primary outcomes. The term trAEs was defined as all the adverse events that deemed to be treatment-related toxicities, based on the reporting of each original trial. The adverse events that were not described in the original trials as treatment-related were excluded. To avoid selective reporting, irAEs of both all-grade and high-grade were reported as the secondary outcomes. All the trAEs that deemed to be possible immune-related toxicities were irAEs. The all-grade and high-grade adverse events were defined as Grade 1--5 and Grade 3--5 adverse events, respectively, based on the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.

Data Synthesis and Statistical Analysis
---------------------------------------

Traditional pairwise meta-analyses were calculated using DerSimonian-Laird random-effects model since they were more conservative to deal with heterogeneity ([@B29], [@B30]). The summary effect sizes were presented as pooled odds ratio (OR) and 95% confidence intervals (CIs), with regard to the all-grade and high-grade trAEs and irAEs, respectively. A two-sided *p* \< 0.05 or 95% CIs (excluding one) was regarded as statistically significant. We used the Cochrane *Q* statistic and quantified with *I*^2^ statistics to evaluate the heterogeneity among studies. An *I*^2^ value over 50% indicated substantial heterogeneity. Publication bias was examined using funnel plots ([@B31]).

NMA were performed based on Bayesian framework using a Markov Chain Monte Carlo (MCMC) simulation technique. The posterior distribution of all parameters was estimated using non-informative priors ([@B32]). The MCMC model was updated with 100,000 simulated draws after a burn-ins of 20,000 iterations and used a thinning interval of 10 for each chain. The adequacy of burn-in and convergence were assessed using the Brooks-Gelman-Rubin statistic ([@B33]). We reported the relative adverse effects of treatments as OR along with corresponding 95% credible intervals (Crls). Random-effects model was used since they generally showed better goodness of fit. Relative risks (RRs) and corresponding 95% CrIs were also calculated to estimate the incidence of trAEs and irAEs for each treatment (Incidence = 100 × assumed placebo risk × RR, the assumed placebo risk was generated by using traditional meta-analyses with random-effects model).

We calculated the posterior mean of the residual deviance to determine goodness of fit of the models. Ideally, each data point should contribute about one to the posterior mean of the residual deviance. It can be compared with the number of data points for model fit checking.

The median ranks and surface under the cumulative ranking curve (SUCRA) were estimated for all the arms and to obtain the hierarchy of safety. SUCRA was the percentage of drug safety on the adverse events that would be ranked first without uncertainty. When the drug safety is certain to be the best, the SUCRA value equals one. It equals zero when the safety is certain to be the worst ([@B34]).

Since consistency (defined as agreement) between direct and indirect results is the key to robust results, the presence of inconsistency was first evaluated by node splitting analysis in the entire network on particular comparisons ([@B35], [@B36]). Then we used the loop-specific approach to evaluate the presence of inconsistency in each loop ([@B37]). We calculated the values of two odds ratios (RoR) from direct and indirect evidence with 95% CI. *P*-value of \<0.05 was regarded as significant inconsistency.

Meta-regression analyses were performed by adding pre-specified covariates (i.e., median age, percentage of male, line of treatment, tumor histology, whether double-blind design was used) to the network meta-analysis models. Sensitivity analyses were performed based on phase III trials only to evaluate the robustness of results. Subgroup analyses were conducted based on type of cancer (NSCLC and melanoma) and line of treatment (first-line, second, or higher line). The data analyses were conducted using STATA version 14.0 and WinBUGs version 1.4.3.

Results {#s3}
=======

Selection of Trials
-------------------

Literature search initially identified 4,274 unduplicated articles, 4,217 of which were excluded after review of titles and abstracts. A total of 57 full-text articles were assessed for eligibility. Finally, 27 articles including 23 randomized controlled trials (RCTs) were included for quantitative synthesis ([Figure 1](#F1){ref-type="fig"}) ([@B1]--[@B6], [@B19]--[@B23], [@B38]--[@B53]).

![Literature search and selection.](fonc-09-00972-g0001){#F1}

Characteristics of Trials and Patients
--------------------------------------

The 23 RCTs covered six treatment strategies and involved a total of 14,204 patients with cancer in the safety data set ([Figure 2](#F2){ref-type="fig"}). Of the 23 included RCTs, 12 studied first-line treatment. Eight were phase III trials with double-blind design. Cancer types investigated included lung cancer ([@B13]), melanoma ([@B4]), gastric or gastro-esophageal junction cancer ([@B2]), urothelial carcinoma ([@B2]), breast cancer ([@B1]), head and neck carcinoma ([@B1]). PD-1 inhibitor (anti-PD-1) and PD-L1 inhibitor (anti-PD-L1) were evaluated in 17 and 6 trials, respectively. The baseline characteristics of included trials are listed in [Table 1](#T1){ref-type="table"}. The risk of bias summary for included trials is listed in [Supplementary Table 2](#SM5){ref-type="supplementary-material"}.

![Network plots of eligible comparisons for the Bayesian network meta-analysis. The size of the nodes is proportional to the number of patients (in parentheses) randomized to receive the treatment. The width of the lines is proportional to the number of comparisons (beside the line) comparing the connected treatment (nodes). A total of 23 comparisons were analyzed for treatment-related adverse events **(A)**; a total of 11 comparisons were analyzed for immune-related adverse events **(B)**.](fonc-09-00972-g0002){#F2}

###### 

Characteristics of included trials (27 articles including 23 randomized controlled trials).

  **Trial name**                       **Line of treatment**   **Study phase**   **Blinding**   **Median age (range)**   **Sex (male)**   **Tumor type**                                 **Treatment (number of patients in randomization)**                                                                                                                                                        **Follow up months**   **Number of patients in safety dataset**   **Treatment-related adverse events**   **Immune-related adverse events**         
  ------------------------------------ ----------------------- ----------------- -------------- ------------------------ ---------------- ---------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- ------------------------------------------ -------------------------------------- ----------------------------------- ----- ----
  CheckMate 017 ([@B45])               Second-line             Phase 3           Open-label     63 (39--85)              208              Non-small-cell lung cancer                     Nivolumab 3 mg/kg every 2 weeks (135)                                                                                                                                                                      Minimum 11.1           131                                        76                                     9                                   NA    NA
                                                                                                                                                                                         Docetaxel 75 mg/m^2^ every 3 weeks (137)                                                                                                                                                                   Minimum 11.1           129                                        111                                    74                                  NA    NA
  CheckMate 026 ([@B49])               First-line              Phase 3           Open-label     64 (29--89)              332              Non-small-cell lung cancer                     Nivolumab 3 mg/kg every 2 weeks (271)                                                                                                                                                                      Median 13.5            267                                        190                                    49                                  NA    NA
                                                                                                                                                                                         Platinum doublet chemotherapy every 3 weeks (270)                                                                                                                                                          Median 13.5            263                                        243                                    136                                 NA    NA
  CheckMate 037 ([@B20], [@B44])       Second-line             Phase 3           Open-label     60 (23--85)              261              Melanoma                                       Nivolumab 3 mg/kg every 2 weeks (272)                                                                                                                                                                      Median 8.4             268                                        206                                    37                                  NA    NA
                                                                                                                                                                                         Dacarbazine 1,000 mg/m^2^ every 3 weeks or carboplatin AUC = 6 plus paclitaxel 175 mg/m^2^ every 3 weeks (133)                                                                                             Median 8.4             102                                        84                                     35                                  NA    NA
  CheckMate 057 ([@B46])               Second-line             Phase 3           Open-label     62 (21--85)              319              Non-small-cell lung cancer                     Nivolumab 3 mg/kg every 2 weeks (292)                                                                                                                                                                      Minimum 13.2           287                                        199                                    30                                  NA    NA
                                                                                                                                                                                         Docetaxel 75 mg/m^2^ every 3 weeks (290)                                                                                                                                                                   Minimum 13.2           268                                        236                                    144                                 NA    NA
  CheckMate 066 ([@B2], [@B23])        First-line              Phase 3           Double-blind   65 (18--87)              246              Melanoma                                       Nivolumab 3 mg/kg every 2 weeks (210)                                                                                                                                                                      Median 8.9             206                                        160                                    31                                  NA    NA
                                                                                                                                                                                         Dacarbazine 1,000 mg/m^2^ every 3 weeks (208)                                                                                                                                                              Median 6.8             205                                        159                                    36                                  NA    NA
  CheckMate 227 ([@B47])               First-line              Phase 3           Open-label     64 (29--87)              NA               Non-small-cell lung cancer                     Nivolumab 240 mg every 2 weeks (573)                                                                                                                                                                       Minimum 11.2           391                                        251                                    76                                  NA    NA
                                                                                                                                                                                         Platinum doublet chemotherapy based on tumor histologic type every 3 weeks (583)                                                                                                                           Minimum 11.2           570                                        460                                    216                                 NA    NA
  IMpassion130 ([@B6])                 First-line              Phase 3           Double-blind   55 (20--86)              0                Breast cancer                                  Atezolizumab 840 mg on days 1 and 15 plus nab-paclitaxel 100 mg/m^2^ on days 1, 8, and 15 every 4 weeks (451)                                                                                              Median 12.9            452                                        436                                    182                                 259   34
                                                                                                                                                                                         NAb-paclitaxel 100 mg/m^2^ on days 1, 8, and 15 every 4 weeks (451)                                                                                                                                        Median 12.9            438                                        410                                    133                                 183   19
  IMpower133 ([@B5])                   First-line              Phase 3           Double-blind   64 (26--90)              261              Small-cell lung cancer                         Carboplatin AUC = 5 every 3 weeks and etoposide 100 mg/m^2^ with atezolizumab 1,200 mg (201)                                                                                                               Median 13.9            198                                        188                                    115                                 79    NA
                                                                                                                                                                                         Carboplatin AUC = 5 every 3 weeks and etoposide 100 mg/m^2^ (202)                                                                                                                                          Median 13.9            196                                        181                                    113                                 48    NA
  IMvigor211 ([@B52])                  First-line              Phase 3           Open-label     67 (31--88)              718              Urothelial carcinoma                           Atezolizumab 1,200 mg every 3 weeks (467)                                                                                                                                                                  Median 17.3            459                                        319                                    95                                  139   37
                                                                                                                                                                                         Vinflunine 320 mg/m^2^, paclitaxel 175 mg/m^2^, or docetaxel 75 mg/m^2^ every 3 weeks (464)                                                                                                                Median 17.3            443                                        395                                    198                                 98    14
  KEYNOTE-002 ([@B1], [@B39])          Second-line or more     Phase 2           Open-label     62 (15--89)              327              Melanoma                                       Pembrolizumab 2 mg/kg every 3 weeks (180)                                                                                                                                                                  Median 10              178                                        125                                    24                                  NA    NA
                                                                                                                                                                                         Pembrolizumab 10 mg/kg every 3 weeks (181)                                                                                                                                                                 Median 10              179                                        136                                    30                                  NA    NA
                                                                                                                                                                                         Paclitaxel plus carboplatin, paclitaxel, carboplatin, dacarbazine, or oral temozolomide (179)                                                                                                              Median 10              171                                        138                                    45                                  NA    NA
  KEYNOTE-010 ([@B40])                 Second-line or more     Phase 2/3         Open-label     63 (56--69)              634              Non-small-cell lung cancer                     Pembrolizumab 2 mg/kg every 3 weeks (345)                                                                                                                                                                  Median 13.1            339                                        215                                    43                                  NA    NA
                                                                                                                                                                                         Pembrolizumab 10 mg/kg every 3 weeks (346)                                                                                                                                                                 Median 13.1            343                                        226                                    55                                  NA    NA
                                                                                                                                                                                         Docetaxel 75 mg/m^2^ every 3 weeks (343)                                                                                                                                                                   Median 13.1            309                                        251                                    109                                 NA    NA
  KEYNOTE-021 ([@B50])                 First-line              Phase 3           Open-label     63 (54--70)              48               Non-small-cell lung cancer                     Pembrolizumab 200 mg every 3 weeks plus pemetrexed 500 mg/m^2^ and carboplatin AUC = 5 every 3 weeks followed by pembrolizumab for 24 months and optional indefinite pemetrexed maintenance therapy (60)   Median 10.6            59                                         55                                     23                                  13    2
                                                                                                                                                                                         Pemetrexed 500 mg/m^2^ and carboplatin AUC = 5 followed by optional indefinite pemetrexed maintenance therapy (63)                                                                                         Median 10.6            62                                         56                                     16                                  7     1
  KEYNOTE-024 ([@B22])                 First-line              Phase 3           Open-label     65 (33--90)              187              Non-small-cell lung cancer                     Pembrolizumab 200 mg every 3 weeks (154)                                                                                                                                                                   Median 11.2            154                                        113                                    41                                  45    15
                                                                                                                                                                                         Carboplatin plus pemetrexed, cisplatin plus pemetrexed, carboplatin plus gemcitabine, cisplatin plus gemcitabine, or carboplatin plus paclitaxel (151)                                                     Median 11.2            150                                        135                                    80                                  7     1
  KEYNOTE-040 ([@B3])                  First-line              Phase 3           Open-label     60 (54--66)              412              Head and neck carcinoma                        Pembrolizumab 200 mg every 3 weeks (247)                                                                                                                                                                   Median 7.5             246                                        155                                    33                                  63    11
                                                                                                                                                                                         Methotrexate 40 mg/m^2^ or docetaxel 75 mg/m^2^ every 3 weeks or cetuximab 250 mg/m^2^ per week following a loading dose of 400 mg/m^2^ (248)                                                              Median 7.1             234                                        196                                    85                                  28    11
  KEYNOTE-045 ([@B43])                 Second-line             Phase 3           Open-label     66 (26--88)              402              Urothelial carcinoma                           Pembrolizumab 200 mg every 3 weeks (270)                                                                                                                                                                   Median 14.1            266                                        162                                    40                                  45    12
                                                                                                                                                                                         Paclitaxel 175 mg/m^2^ every 3 weeks or docetaxel 75 mg/m^2^ or vinflunine 320 mg/m^2^ every 3 weeks (272)                                                                                                 Median 14.1            255                                        230                                    126                                 19    4
  KEYNOTE-054 ([@B53])                 Second-line or more     Phase 3           Double-blind   54 (19--88)              628              Melanoma                                       Pembrolizumab 200 mg every 3 weeks (514)                                                                                                                                                                   Median 15              509                                        396                                    75                                  190   36
                                                                                                                                                                                         Placebo (505)                                                                                                                                                                                              Median 15              502                                        332                                    17                                  45    3
  KEYNOTE-061 ([@B38])                 First-line              Phase 3           Open-label     61 (53--70)              410              Gastric or gastro-esophageal junction cancer   Pembrolizumab 200 mg every 3 weeks (296)                                                                                                                                                                   Median 8.5             294                                        155                                    42                                  NA    NA
                                                                                                                                                                                         Paclitaxel 80 mg/m^2^ every 4 weeks (296)                                                                                                                                                                  Median 7.5             276                                        232                                    96                                  NA    NA
  KEYNOTE-189 ([@B41])                 First-line              Phase 3           Double-blind   64 (34--84)              363              Non-small-cell lung cancer                     Pembrolizumab 200 mg every 3 weeks plus pemetrexed and a platinum-based drug every 3 weeks followed by pemetrexed maintenance therapy (410)                                                                Median 10.5            405                                        NA                                     NA                                  92    36
                                                                                                                                                                                         Pemetrexed and a platinum-based drug every 3 weeks followed by pemetrexed maintenance therapy (206)                                                                                                        Median 10.5            202                                        NA                                     NA                                  24    9
  KEYNOTE-407 ([@B42])                 First-line              Phase 3           Double-blind   65 (29--88)              455              Non-small-cell lung cancer                     Pembrolizumab 200 mg plus carboplatin 6 mg/m^2^ and paclitaxel 200 mg/m^2^ or nab-paclitaxel 100 mg/m^2^ every 3 weeks (278)                                                                               Median 7.8             278                                        NA                                     NA                                  80    30
                                                                                                                                                                                         Carboplatin 6 mg/m^2^ and paclitaxel 200 mg/m^2^ or nab-paclitaxel 100 mg/m^2^ every 3 weeks (281)                                                                                                         Median 7.8             280                                        NA                                     NA                                  24    9
  OAK ([@B51])                         Second-line or more     Phase 3           Open-label     63 (33--85)              747              Non-small-cell lung cancer                     Atezolizumab 1,200 mg every 3 weeks (613)                                                                                                                                                                  Median 21              609                                        390                                    90                                  NA    NA
                                                                                                                                                                                         Docetaxel 75 mg/m^2^ every 3 weeks (612)                                                                                                                                                                   Median 21              578                                        496                                    248                                 NA    NA
  ONO-4538-12, ATTRACTION-2 ([@B48])   Second-line or more     Phase 3           Double-blind   62 (53--69)              348              Gastric or gastro-esophageal junction cancer   Nivolumab 3 mg/kg every 2 weeks (330)                                                                                                                                                                      Median 8.9             330                                        141                                    39                                  NA    NA
                                                                                                                                                                                         Placebo (163)                                                                                                                                                                                              Median 8.6             161                                        43                                     9                                   NA    NA
  PACIFIC study ([@B4], [@B21])        Second-line or more     Phase 3           Double-blind   64 (23--90)              500              Non-small-cell lung cancer                     Durvalumab 10 mg/kg every 2 weeks (476)                                                                                                                                                                    Median 25.2            475                                        322                                    63                                  115   20
                                                                                                                                                                                         Placebo (237)                                                                                                                                                                                              Median 25.2            234                                        125                                    13                                  19    9
  POPLAR Study ([@B19])                Second-line or more     Phase 2           Open-label     62 (36--84)              169              Non-small-cell lung cancer                     Atezolizumab 1,200 mg every 3 weeks (144)                                                                                                                                                                  Median 14.8            142                                        95                                     17                                  NA    NA
                                                                                                                                                                                         Docetaxel 75 mg/m^2^ every 3 weeks (143)                                                                                                                                                                   Median 15.7            135                                        119                                    55                                  NA    NA

Treatment-Related Adverse Events (trAEs)
----------------------------------------

Results of pairwise meta-analyses showed that anti-PD-L1 plus chemotherapy was associated with increased all-grade trAEs compared with using chemotherapy alone (OR = 1.74, 95% CI: 1.06--2.88), with high quality of evidence. However, anti-PD-L1 monotherapy was associated with a significant reduction in trAEs compared with chemotherapy (all-grade: OR = 0.29, 95% CI: 0.23--0.35; high-grade: OR = 0.26, 95% CI: 0.20--0.34), with moderate quality of evidence. Compared with placebo, both anti-PD-1 and anti-PD-L1 were associated with significantly increased high-grade trAEs, with moderate to high quality of evidence ([Supplementary Tables 3](#SM6){ref-type="supplementary-material"}, [4](#SM7){ref-type="supplementary-material"}).

Median ranks on treatment-related safety from high to low were: placebo, anti-PD-L1, anti-PD-1, chemotherapy, anti-PD-1 plus chemotherapy, anti-PD-L1 plus chemotherapy for all-grade trAEs; placebo, anti-PD-L1, anti-PD-1, chemotherapy, anti-PD-L1 plus chemotherapy, anti-PD-1 plus chemotherapy for high-grade trAEs ([Supplementary Table 5](#SM8){ref-type="supplementary-material"}). Pooled all-grade and high-grade incidences of trAEs were, respectively, 48.9 and 4.3% for placebo, 60.4 and 6.4% for anti-PD-L1, 65.7 and 6.6% for anti-PD-1, 82.8 and 8.0% for chemotherapy, 87.4 and 8.2% for anti-PD-1 plus chemotherapy, 88.6 and 8.1% for anti-PD-L1 plus chemotherapy.

Results from NMA and SUCRA suggested that, compared with placebo, anti-PD-L1 monotherapy did not increase trAEs significantly (all-grade: OR = 1.62, 95% CrI: 0.85--3.06, SUCRA = 77.2%; high-grade: OR = 2.95, 95% CrI: 1.23--7.07, SUCRA = 73.8%). However, anti-PD-L1 plus chemotherapy had the worst safety on all-grade trAEs (all-grade: OR = 9.62, 95% CrI: 3.60--25.81, SUCRA = 10.1%. Anti-PD-1 plus chemotherapy had the worst safety on high-grade trAEs (OR = 15.52, 95% CrI: 4.90--49.65, SUCRA = 9.3%), with moderate to high quality of evidence ([Figures 3A](#F3){ref-type="fig"}, [4A](#F4){ref-type="fig"}, [Supplementary Table 4](#SM7){ref-type="supplementary-material"}).

![Bayesian network meta-analysis of treatment-related and immune-related adverse events. Comparisons should be read from the top treatment to the bottom treatment. Bold underline cells are significant. Results represent pooled odds ratios and 95% credible intervals for treatment-related adverse events **(A)** and immune-related adverse events **(B)**. Odds ratio \>1 favors the bottom treatment.](fonc-09-00972-g0003){#F3}

![Cluster SUCRA ranking plots and incidence. **(A)** Cluster SUCRA ranking plot for safety on all-grade and high-grade trAEs (x-axis: SUCRA ranking for safety on high-grade trAEs; y-axis: SUCRA ranking for safety on all-grade trAEs) and incidence. **(B)** Cluster SUCRA ranking plot for safety on all-grade and high-grade irAEs (x-axis: SUCRA ranking for safety on high-grade irAEs; y-axis: SUCRA ranking for safety on all-grade irAEs) and incidence. For trAEs and irAEs, higher SUCRA ranking = safer treatment with lower risk of adverse events. Numbers in parenthesis represent 95% CIs derived by replacing the relative risks in the calculation with the lower and upper limits of their respective 95% CrIs. irAEs, immune-related adverse events; trAEs, treatment-related adverse events.](fonc-09-00972-g0004){#F4}

When comparative safety was assessed, anti-PD-L1 and anti-PD-1 were superior to all other treatments (not include placebo) for the safety on high-grade trAEs. Anti-PD-L1 and anti-PD-1 were comparable with each other for trAEs (all-grade: OR = 1.26, 95% CrI: 0.74--2.17; high-grade: OR = 1.15, 95% CrI: 0.58--2.29), both with high quality of evidence. When combined with chemotherapy, anti-PD-L1 and anti-PD-1 were also comparable with each other for trAEs (all-grade: OR = 0.88, 95% CrI: 0.15--5.55; high-grade: OR = 1.47, 95% CrI: 0.30--7.30), with high quality of evidence ([Figure 3A](#F3){ref-type="fig"}, [Supplementary Table 4](#SM7){ref-type="supplementary-material"}).

Immune-Related Adverse Events (irAEs)
-------------------------------------

Results of pairwise meta-analyses showed that both anti-PD-1 and anti-PD-L1 and their combination with chemotherapy were associated with increased all-grade irAEs compared with using chemotherapy alone, with low to high quality of evidence. Compared with placebo, anti-PD-1 was associated with increased high-grade irAEs (OR = 12.66, 95% CI: 3.87--41.38, with moderate quality of evidence), whereas anti-PD-L1 was not (OR = 1.10, 95% CI: 0.49--2.45, with moderate quality of evidence; [Supplementary Tables 3](#SM6){ref-type="supplementary-material"}, [4](#SM7){ref-type="supplementary-material"}).

Median ranks on immune-related safety from high to low were: placebo, chemotherapy, anti-PD-L1, anti-PD-L1 plus chemotherapy, anti-PD-1 plus chemotherapy, anti-PD-1 for both all-grade and high-grade irAEs ([Supplementary Table 5](#SM8){ref-type="supplementary-material"}). Pooled all-grade and high-grade incidences of irAEs were, respectively, 11.6 and 2.4% for chemotherapy, 13.3 and 2.8% for anti-PD-L1, 13.9 and 3.0% for anti-PD-L1 plus chemotherapy, 14.9 and 3.2% for anti-PD-1 plus chemotherapy, 15.1 and 3.5% for anti-PD-1.

Results from NMA suggested that, compared with placebo, anti-PD-1 monotherapy increased all-grade irAEs significantly (all-grade: OR = 6.60, 95% CrI: 2.94--15.67, SUCRA = 9.5%; high-grade: OR = 6.36, 95% CrI: 0.74--66.54, SUCRA = 16.8%), with moderate to high quality of evidence ([Figures 3B](#F3){ref-type="fig"}, [4B](#F4){ref-type="fig"}, [Supplementary Table 4](#SM7){ref-type="supplementary-material"}).

When comparative safety was assessed, compared with chemotherapy, anti-PD-1 was associated with increased all-grade irAEs (OR = 3.30, 95% CrI: 1.93--6.32), whereas anti-PD-L1 was not (OR = 1.64, 95% CrI: 0.74--3.89). However, both were with low quality of evidence. Compared with chemotherapy, anti-PD-1 plus chemotherapy was associated with increased all-grade irAEs (OR = 2.95, 95% CrI: 1.52--5.51, with low quality of evidence), whereas anti-PD-L1 plus chemotherapy was not (OR = 1.94, 95% CrI: 0.98--3.95, with high quality of evidence). Anti-PD-L1 and anti-PD-1 were comparable with each other for irAEs (all-grade: OR = 2.01, 95% CrI: 0.84--5.09; high-grade: OR = 2.84, 95% CrI: 0.29--33.13), with high quality of evidence. When combined with chemotherapy, anti-PD-L1 and anti-PD-1 were also comparable with each other for irAEs (all-grade: OR = 1.52, 95% CrI: 0.57--3.78; high-grade: OR = 1.53, 95% CrI: 0.07--31.33), with high quality of evidence ([Figure 3B](#F3){ref-type="fig"}, [Supplementary Table 4](#SM7){ref-type="supplementary-material"}).

Model Fit, Inconsistence Check, and Quality of Evidence
-------------------------------------------------------

The model fit was evaluated using the posterior mean of the residual deviance, which was 42 and 43 for trAEs of all-grade and high-grade, respectively, and was 20 and 19 for irAEs of all-grade and high-grade, respectively. The model\'s overall fit was relatively satisfactory. Inconsistence check showed that neither node splitting analysis nor loop-specific approach showed significant inconsistency between direct and indirect results, which indicated robust results ([Supplementary Tables 6](#SM9){ref-type="supplementary-material"}, [7](#SM10){ref-type="supplementary-material"}). [Supplementary Table 4](#SM7){ref-type="supplementary-material"} summarized the quality of evidence using GRADE framework for the outcomes. Overall, there was no inconsistency of results, indirectness or publication bias. In several direct comparisons, study limitations existed since lack of blinding. In NMA, three comparisons had serious imprecision in summary estimate.

Reporting Bias, Sensitivity Analyses, and Meta-Regression
---------------------------------------------------------

[Supplementary Figure 1](#SM1){ref-type="supplementary-material"} presents the adjusted funnel plot for the network. The funnel plots of all-grade and high-grade of trAEs and irAEs did not show asymmetry, suggesting no potential risk of reporting bias. Sensitivity analyses based on phase III trials did not indicate any major influence on the outcomes ([Supplementary Figures 2](#SM2){ref-type="supplementary-material"}, [3](#SM3){ref-type="supplementary-material"}). Meta-regression analyses did not reveal any pre-specified factors that influenced the estimated effects significantly ([Supplementary Table 8](#SM11){ref-type="supplementary-material"}).

Subgroup Analyses
-----------------

Among patients with NSCLC, median ranks on treatment-related safety from high to low were: placebo, anti-PD-L1, anti-PD-1, chemotherapy, anti-PD-1 plus chemotherapy. Median ranks on immune-related safety from high to low were: chemotherapy, anti-PD-1 plus chemotherapy, anti-PD-1 ([Supplementary Tables 9](#SM12){ref-type="supplementary-material"}, [10](#SM13){ref-type="supplementary-material"}). The pooled incidence of trAEs was highest for anti-PD-1 plus chemotherapy (all-grade: 97.0%; high-grade: 10.7%; [Supplementary Table 11](#SM14){ref-type="supplementary-material"}). Compared with chemotherapy, both anti-PD-1 and anti-PD-L1 were associated with decreased trAEs, whereas anti-PD-1 increased irAEs significantly ([Supplementary Table 12](#SM15){ref-type="supplementary-material"}).

Among patients with melanoma, median ranks on treatment-related safety from high to low were: placebo, anti-PD-1, chemotherapy ([Supplementary Tables 9](#SM12){ref-type="supplementary-material"}, [10](#SM13){ref-type="supplementary-material"}). For anti-PD-1, the pooled incidence was 85.0 and 5.6% for all-grade and high-grade trAEs, respectively ([Supplementary Table 11](#SM14){ref-type="supplementary-material"}).

Among patients with first-line treatment, median ranks on treatment-related safety high to low were anti-PD-L1, anti-PD-1, chemotherapy, anti-PD-1 plus chemotherapy, anti-PD-L1 plus chemotherapy. Median ranks on immune-related safety from high to low were: chemotherapy, anti-PD-L1, anti-PD-L1 plus chemotherapy, anti-PD-1 plus chemotherapy, anti-PD-1 ([Supplementary Tables 9](#SM12){ref-type="supplementary-material"}, [10](#SM13){ref-type="supplementary-material"}). The pooled incidence of trAEs was lowest for anti-PD-L1 (all-grade: 37.8%; high-grade 19.0%), whereas anti-PD-1 had the highest irAEs incidence (all-grade: 27.6%; high-grade: 4.5%; [Supplementary Table 11](#SM14){ref-type="supplementary-material"}). Compared with chemotherapy, anti-PD-1 was associated with decreased trAEs of both all-grade and high-grade. However, anti-PD-1 was associated with increased all-grade irAEs compared with chemotherapy ([Supplementary Table 12](#SM15){ref-type="supplementary-material"}).

Among patients with second or higher line of treatment, median ranks on treatment-related safety from high to low were: placebo, anti-PD-L1, anti-PD-1, chemotherapy ([Supplementary Tables 9](#SM12){ref-type="supplementary-material"}, [10](#SM13){ref-type="supplementary-material"}). The pooled incidence of all-grade trAEs was 65.6 and 60.5% for anti-PD-1 and anti-PD-L1, respectively ([Supplementary Table 11](#SM14){ref-type="supplementary-material"}). Compared with chemotherapy, both anti-PD-1 and anti-PD-L1 decreased trAEs significantly ([Supplementary Table 12](#SM15){ref-type="supplementary-material"}).

Discussion {#s4}
==========

Summary of Key Findings
-----------------------

This NMA compares all anti-PD1/PD-L1-related therapeutic regimens for cancer patients. There are three key findings. First, anti-PD-L1 monotherapy was ranked the best for safety on trAEs. However, when combined with chemotherapy, both anti-PD-L1 and anti-PD-1 were ranked the worst. Second, anti-PD-L1 monotherapy had the lowest irAEs incidence, whereas anti-PD-1 monotherapy had the highest. However, anti-PD-L1 did not decrease irAEs significantly compared with anti-PD-1. Third, both anti-PD-L1 and anti-PD-1 monotherapy decreased high-grade trAEs significantly compared with using chemotherapy alone or combining chemotherapy with anti-PD-1/anti-PD-L1.

Comparison With Other Studies
-----------------------------

One study showed that combinations of conventional therapy with immune checkpoint inhibitors (ICIs) would be associated with increased trAEs compared with taking one ICI drug ([@B17]). Another study showed that anti-PD-1 would slightly increase trAEs compared with anti-PD-L1 ([@B54]). This NMA agreed with these previous findings. In addition, we calculated the safety ranking on trAEs. We found that anti-PD-L1 monotherapy had the lowest incidences on both trAEs and irAEs among anti-PD-1/anti-PD-L1-related therapeutic regimens.

Xu et al. reported all-grade trAEs incidences of 73.5 and 66.4% for anti-PD-1 and anti-PD-L1, respectively ([@B17]). In our study, lower pooled incidence of trAEs was obtained, which was 65.7 and 60.4% for anti-PD-1 and anti-PD-L1, respectively. Xu et al. used all adverse events if trAE was not available ([@B17]), whereas we used trAEs data only. Thus, the overall incidence would not be overestimated. Pillai et al. compared irAEs between anti-PD-1 and anti-PD-L1 among patients with NSCLC ([@B54]). Both would lead to 3.0% high-grade irAEs incidence. Our study included patients with all types of cancer who showed an incidence of 3.5 and 2.8% for anti-PD-1 and anti-PD-L1, respectively. In addition, we found that anti-PD-1 monotherapy would increase irAEs compared with chemotherapy, whereas anti-PD-L1 monotherapy would not. Compared with placebo, all the anti-PD-1/anti-PD-L1-related therapeutic regimens would increase all-grade irAEs, but not high-grade irAEs.

Strength and Limitations of Study
---------------------------------

This NMA fills a crucial knowledge gap regarding the comparative risks of both trAEs and irAEs among PD-1/PD-L1 inhibitors and their combination with chemotherapy. However, four limitations should be noted. First, each individual drug would have its distinct toxicity profile. However, data analyses in this study were performed by classifying drugs according to the mechanism of action rather than analyzing the drugs separately due to a limited number of trials available at this moment so as to avoid yielding very sparse networks. Combining different drugs of the same class within a single category of targeted agent may introduce heterogeneity in the NMA. Nevertheless, the random-effects model was used and the model\'s overall fit was satisfactory. More original trials are still awaited to explore more about the toxicity profiles for each drug. Second, indirect comparisons from NMA may suffer bias through confounding by study-level characteristics. Results from indirect comparisons should be interpreted with caution as direct comparison is lacking. However, we included RCTs only in this NMA, thus the trial populations and study characteristics were comparable to the target population. Potential confounding factors were further evaluated using meta-regression analyses, which had no major influence on the results. Third, node split analysis showed a *P*-value of 0.08 in four comparisons of high-grade irAEs. Despite there being no statistical inconsistency, further evidence with outstanding consistency is still needed when more trials are available for these comparisons. Last but not least, immune-related diseases are usually late onset, thus the incidence of irAEs may be underestimated due to limited follow-up time of the included trials.

Clinical and Research Implications
----------------------------------

This current study sheds light on the important clinical issue about the comparative safety on both trAEs and irAEs from anti-PD-L1/anti-PD-1-related treatment. Our results demonstrated that anti-PD-L1 was well-tolerated for all cancer patients. A previous study showed that different tumor histologies may have different irAEs profiles ([@B55]). In our study, results of meta-regression showed that tumor histology did not influence the estimated effects.

Among patients with NSCLC, Xu et al. stated that nivolumab (anti-PD-1) rather than anti-PD-L1 would be ranked the best for safety on trAEs. However, this finding could be considered with caution in clinical practice. First, PACIFIC study was not included in their analysis ([@B4], [@B21]). We found that anti-PD-L1 monotherapy was still ranked the best for all-grade trAEs if the PACIFIC study was included among NSCLC. Second, we found that among the nivolumab trials available, none of them reported all-grade or high-grade irAEs. It will be interesting to learn how the conclusion changes with more irAEs data being reported. The immune-related safety needs to be investigated further for nivolumab.

There are two research implications. First, the irAEs associated with anti-PD-1/anti-PD-L1 may be distinct. For example, anti-PD-1 agents may have higher risk of immune-related pneumonitis, whereas, anti-PD-L1 agents may have higher hypothyroidism risk ([@B56]). More studies should be conducted in the future base on organ specific immune-related adverse events, especially focusing on colitis, hepatitis (aspartate aminotransferase), pneumonitis, hypothyroidism, and rash. Second, in real-world clinical practice, it is still challenging to discern irAEs since adverse events, such like pneumonitis and colitis, may be caused by non-immune-related reactions. In the future, it is important to publish standardized method to specify the clinical criteria for irAEs.

Conclusion {#s5}
==========

Anti-PD-L1 monotherapy was ranked the best for safety on trAEs, whereas anti-PD-1/anti-PD-L1 plus chemotherapy was ranked the worst. Among the anti-PD-1/PD-L1-related therapeutic regimens, anti-PD-L1 had the best irAEs safety, whereas anti-PD-1 had the worst. Anti-PD-1 did not increase trAEs or irAEs significantly compared with anti-PD-L1. Awareness surrounding the comparative safety of trAEs and irAEs from anti-PD-1/PD-L1-related therapeutic regimens could promote further appropriate utilization of these agents in clinical practice.
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Comparison---adjusted funnel plot for the network. Adjusted funnel plot for the network for all-grade treatment-related adverse events **(A)**, high-grade treatment-related adverse events **(B)**, all-grade immune-related adverse events **(C)**, and high-grade immune-related adverse events **(D)**. The red line represents the null hypothesis that the study-specific effect sizes do not differ from the respective comparison-specific pooled effect estimates. The blue line is the regression line. Different colors correspond to different comparisons. 01, Placebo; 02, Chemotherapy; 03, anti-PD-L1 plus chemotherapy; 04, anti-PD-L1; 05, anti-PD-1 plus chemotherapy; 06, anti-PD-1 inhibitors.
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###### 

Bayesian network meta-analysis of treatment-related and immune-related adverse events (sensitivity analysis). Comparisons should be read from the top treatment to the bottom treatment. Bold underline cells are significant. Results represent pooled odds ratios and 95% credible intervals for treatment-related adverse events **(A)** and immune-related adverse events **(B)**. Odds ratio \>1 favors the bottom treatment.

###### 

Click here for additional data file.

###### 

Cluster SUCRA ranking plots (sensitivity analysis). **(A)** Cluster SUCRA ranking plot for safety on all-grade and high-grade trAEs (x-axis: SUCRA ranking for safety on high-grade trAEs; y-axis: SUCRA ranking for safety on all-grade trAEs). **(B)** Cluster SUCRA ranking plot for safety on all-grade and high-grade irAEs (x-axis: SUCRA ranking for safety on high-grade irAEs; y-axis: SUCRA ranking for safety on all-grade irAEs). For trAEs and irAEs, higher SUCRA ranking = safer treatment with lower risk of adverse events. irAEs, immune-related adverse events; trAEs, treatment-related adverse events.
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Search strategies.

###### 

Click here for additional data file.

###### 

Risk of bias summary.
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Results of traditional pairwise meta-analyses for different outcomes.
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Evaluation of the quality of evidence using GRADE framework for outcomes.
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Median ranks on safety (rank 1--6 on each scale) and 95% CrIs.
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Nodesplit analysis of network meta-analysis for treatment-related adverse events and immune-related adverse events.

###### 

Click here for additional data file.

###### 

Evaluation of inconsistency using loop-specific heterogeneity estimates.
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Meta-regression for treatment-related adverse events and immune-related adverse events.
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Subgroup analysis: median ranks on safety (rank 1--6 on each scale) and 95% CrIs.
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SUCRA rankings in the subgroup analysis based on type of cancer and line of treatment.
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Pooled incidence along with corresponding 95% credible intervals of treatment based on type of cancer and line of treatment.
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Bayesian network meta-analysis based on type of cancer and line of treatment.
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AEs

:   adverse events

CIs

:   confidence intervals

CrIs

:   credible intervals

FDA

:   Food and Drug Administration

ICIs

:   immune checkpoint inhibitors

irAEs

:   immune-related adverse events

NA

:   not available

NE

:   not estimable

NSCLC

:   non-small cell lung cancer

OR

:   odds ratio

PD-1

:   programmed cell death 1

PD-L1

:   programmed cell death-ligand 1

trAEs

:   treatment-related adverse events.
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